Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 56,900 shares, a growth of 49.0% from the October 15th total of 38,200 shares. Based on an average daily volume of 28,900 shares, the short-interest ratio is presently 2.0 days.

Analyst Ratings Changes

Several equities research analysts recently issued reports on BNTC shares. Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a research report on Friday, October 18th. Oppenheimer started coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $35.00 price target on the stock. Guggenheim began coverage on shares of Benitec Biopharma in a report on Thursday, September 12th. They issued a “buy” rating and a $17.00 price target for the company. Leerink Partners began coverage on shares of Benitec Biopharma in a research note on Monday, July 22nd. They set an “outperform” rating and a $13.00 price objective on the stock. Finally, JMP Securities upped their target price on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a report on Monday, October 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Benitec Biopharma has a consensus rating of “Buy” and a consensus target price of $22.60.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $10.44 on Thursday. The business has a fifty day moving average of $9.85 and a 200-day moving average of $9.01. Benitec Biopharma has a 1 year low of $2.69 and a 1 year high of $12.89.

Institutional Trading of Benitec Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in shares of Benitec Biopharma by 20.3% in the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 1,102 shares in the last quarter. Simplify Asset Management Inc. bought a new position in Benitec Biopharma during the 2nd quarter valued at $358,000. Janus Henderson Group PLC raised its stake in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 64,092 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in Benitec Biopharma in the second quarter worth about $5,881,000. 52.19% of the stock is currently owned by institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.